Abstract-Aldosterone plays a role in hypertension, and hypertension is prevalent in patients with insulin resistance.
T he most important physiological role of aldosterone is to control water homeostasis and electrolytes balance. High levels of adrenal aldosterone secretion cause hypertension, that is, primary aldosteronism, a well-known form of secondary hypertension. Moreover, high plasma aldosterone levels predict the development of hypertension. 1 In view of the fact that aldosterone is a mineral corticosteroid, the association of aldosterone and hypertension is not doubted. Recently, the association between aldosterone and obesity or insulin resistance has attracted much attention. Experimental evidence suggests an interaction between aldosterone and insulin. 2 Aldosterone induces hypokalemia, which may modulate insulin secretion, has direct effects on insulin receptor function, 3, 4 causes pancreatic ␤-cell dysfunction or even apoptosis, 5 interferes with insulin signaling pathways, 6 and decreases insulin sensitivity in human adipocytes in vitro. 7 Moreover, aldosterone reduces the expression of insulinsensitizing factors, such as adiponectin and peroxisome proliferator-activated receptor-␥, in obese, diabetic mice. 8 In addition to the above-mentioned in vitro and animal studies, several clinical studies reported an association between plasma aldosterone levels and insulin resistance. Plasma aldosterone levels are elevated in hypertensive obese subjects. 9 Cross-sectional studies have shown an association between plasma aldosterone levels and insulin resistance in hypertensive and normotensive subjects. 10, 11 Moreover, insulin resistance was restored by surgical intervention or mineralocorticoid receptor blocker in primary hyperaldosteronism. 12 However, contradictory results were reported by other investigators showing no difference of glucose metabolism in a relatively small number of subjects with primary hyperaldosteronism and essential hypertension 13 and showing no changes of glucose metabolism after treatment of primary hyperaldosteronism. 14 Thus, some clinical studies suggest a causal relationship between aldosterone and insulin resistance, but others indicate that insulin sensitivity in primary aldosteronism is no worse than in essential hypertension. 15 Accordingly, we conducted a longitudinal study in subjects in a general population without insulin resistance at baseline to clarify the relationship between circulating aldosterone levels and development of insulin resistance.
Methods

Study Population
A periodic epidemiological survey was performed in 1999 and 2009 in a rural farming community located in southwestern Japan (Tanushimaru town). 16 Tanushimaru was a Japanese cohort of the Seven Countries Study. 16, 17 As reported previously, 18 the demographic backgrounds of the subjects in this area were similar to those of the general Japanese population, and the dietary pattern in this district examined in 1999 was similar to that of the National Nutrition Survey in Japan. 18 We examined 1235 persons over the age of 40 years. From this study, we excluded 147 diabetic subjects, namely, subjects with high fasting plasma glucose Ն126 mg/dL, subjects with hemoglobin A 1c (HbA 1c ) Ն6.0%, and/or those taking oral hypoglycemic agents or receiving insulin injections. In the remaining 1088 subjects, a cross-sectional analysis was performed to examine the relationship between plasma aldosterone levels and insulin resistance. Then we excluded subjects with insulin resistance at baseline (nϭ123). A total of 965 subjects were enrolled for prospective analysis. Ten years later, in 2009, we conducted a follow-up health examination in the same cohort. Of the 965 subjects, 141 died during follow-up and 260 refused the reexamination. Of the 141 deceased, 61 (43.3%) died from cancer and 32 (22.7%) died from cerebrocardiovascular disease, 27 (19.1%) died from infection, and 21 (14.9%) died from other causes. Consequently, a complete data set was available for 564 subjects (215 men and 349 women) in the prospective study.
Data Collection
Medical history, smoking habits, and alcohol intake were ascertained by a questionnaire. Alcohol intake and smoking were classified as current habitual use or no use. Height and weight were measured, and body mass index (BMI) was calculated as an index of obesity. Waist circumference was measured at the level of umbilicus in the standing position. Blood pressure (BP) was measured in the supine position twice at 3-minute intervals using a standard sphygmomanometer. Vigorous physical activity and smoking were avoided for Ն30 minutes before BP measurement. The second BP was taken after 5 deep breaths, and systolic and fifth-phase diastolic pressures were used for analysis.
Blood was drawn from the antecubital vein in the morning after a 12-hour fast for determinations of lipids profiles (total cholesterol, triglycerides, high-density lipoprotein cholesterol [HDL] , and lowdensity lipoprotein cholesterol), fasting plasma glucose, HbA 1c , insulin, serum urea nitrogen, creatinine, uric acid, and aldosterone. Fasting blood samples were centrifuged within 1 hour after collection. Plasma aldosterone was measured in the morning by radioimmunoassay, and samples were taken after the subjects had remained in a sitting position for 10 minutes both at baseline (Kyodo Igaku Laboratory, Fukuoka, Japan) and at the follow-up (SRL, Fukuoka, Japan). The intra-assay and interassay coefficients of variation of aldosterone at the commercially available laboratory that performed the assays (Kyodo Igaku Laboratory) were 4.5% and 4.7%, respectively.
The homeostasis model assessment (HOMA) index [fasting plasma glucose (mg/dL)ϫinsulin (U/mL)/405] was calculated from fasting glucose and insulin level as a marker of insulin resistance. 19 Insulin resistance was defined as HOMA Ն1.73 according to the diagnostic criteria used in Japan. 20 -23 Subjects with fasting plasma glucose Ն126 mg/dL, subjects with HbA 1c Ն6.0%, and/or subjects taking oral hypoglycemic agents or receiving insulin injection were considered to be diabetic. Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease study equation modified with a Japanese coefficient. 24 This study was approved by the Tanushimaru branch of the Japan Medical Association and by the local mayor, as well as by the ethics committee of Kurume University School of Medicine. All of the participants gave informed consent.
Data Analysis
Because of skewed distributions, natural logarithmic transformations were performed for aldosterone, HOMA index, and triglycerides. Log-transformed values were used for the statistical calculation and reconverted to antilogarithm forms in the tables. The medications for hypertension, hyperlipidemia, and diabetes; sex; smoking habits; and alcohol intake were used as dummy variables.
First, we performed univariate regression analyses for correlates of plasma aldosterone levels in the 1088 diabetic-free subjects at baseline in the cross-sectional study. Then, to determine independent correlates, multiple stepwise linear regression analysis was carried out. Next, we divided plasma aldosterone levels of the 564 subjects in the prospective study into tertiles. To obtain relative risks for the development of insulin resistance, we performed Poisson regression analysis after adjusting for confounding factors. Statistical significance was defined as PϽ0.05. All of the statistical analyses were performed using the SAS system (release 9.2; SAS Institute, Cary, NC). Table 1 shows baseline characteristics of the 1088 participants in the cross-sectional study performed in 1999. Hypertension is the most common finding. There were 475 hypertensives (43.6%) at baseline. Of these, 371 subjects (78.1%) were grade I, 80 (16.8%) were grade II, and 24 (5.1%) were grade III according to the World Health Organization criteria. Mean aldosterone level was 3.26Ϯ1.94 ng/dL. Univariate regression analyses for correlates of plasma aldosterone level at baseline were shown in Table 2 . There was a significant relationship between aldosterone and age (PϽ0.001; inversely), BMI (PϽ0.05), waist circumference (PϽ0.01), glucose (PϽ0.05), insulin (PϽ0.001), HOMA index (PϽ0.001), triglycerides (PϽ0.001), and medication for hyperlipidemia (PϽ0.05). Because these parameters could be closely correlated, multiple stepwise regression analysis was performed ( Table 3 ). The analysis showed that age (PϽ0.001; inversely), triglycerides (PϽ0.001), medication for hyperlipidemia (Pϭ0.021), and HOMA index (Pϭ0.029) were independently correlated with plasma aldosterone levels (R 2 ϭ0.083).
Results
Cross-Sectional Study
Prospective Study
Baseline and follow-up mean and percentage differences stratified by the development of insulin resistance were shown in Table 4 . Of 564 subjects without insulin resistance at baseline, 151 subjects developed insulin resistance. Fourteen subjects (2.5%) developed diabetes mellitus. Baseline aldosterone (PϽ0.05), age (PϽ0.001), BMI (PϽ0.01), waist circumference (PϽ0.01), systolic (PϽ0.001) and diastolic BPs (PϽ0.01), glucose (PϽ0.001), HbA 1c (PϽ0.001), insulin (PϽ0.001), and HOMA index (PϽ0.001) were significantly higher in the group that developed insulin resistance than in the group that did not. HDL (PϽ0.01) and medication for hypertension (PϽ0.001) were significantly lower in the group that developed insulin resistance. At the 10-year follow-up, aldosterone (PϽ0.05), age (PϽ0.001), BMI (PϽ0.01), waist circumference (PϽ0.01), glucose (PϽ0.001), HbA 1c (PϽ0.001), insulin (PϽ0.001), HOMA index (PϽ0.001), and triglycerides (PϽ0.001) were significantly higher in the group that developed insulin resistance than in the group that did not. HDL (PϽ0.001) and medication for hypertension (PϽ0.01) were significantly lower in the group that developed insulin resistance. We divided baseline plasma aldosterone levels into tertiles and obtained relative risks for the predictability of the development of insulin resistance (Table 5 ). In the lowest tertile of aldosterone (Յ2.5 ng/dL), 36 subjects developed insulin resistance, whereas in the middle (2.6 -4.6 ng/dL) and the highest (Ն4.7 ng/dL) tertiles, 58 and 57 subjects developed insulin resistance, respectively. A significant (PϽ0.05) relative risk in the final model (model 6; 1.71 [95% CI: 1.03-2.84]) for the development of insulin resistance (adjusted for baseline values of age, sex, BMI, waist circumference, HOMA index and systolic BP, HDL cholesterol, and medication for hypertension) was demonstrated in the highest aldosterone tertile compared with the lowest tertile.
Discussion
Cross-Sectional Study
Plasma aldosterone levels were reportedly associated with obesity or insulin resistance 9 -11 in cross-sectional studies. Univariate regression analysis (Table 2 ) showed a significant cross-sectional relationship of aldosterone with not only HOMA (index of insulin resistance) but also components of the metabolic syndrome (BMI, waist circumference, and triglycerides). Thus, our findings are consistent with those reported by others. 10, 11, 25, 26 Because insulin resistance, BMI, waist circumference, and triglycerides are correlated, we performed multivariate stepwise regression analysis. Our results indicate the independent and positive association of plasma aldosterone with insulin resistance. There is 1 earlier report indicating a similar positive association but only for hypertensive men. 27 Our study extends the previous finding not only to hypertensive patients but also to a general population. The association of aldosterone with BP is well known. However, in our cross-sectional study, aldosterone was not associated with BP. The reason is not clear but could be because of the inclusion of many subjects on antihypertensive medications (201 of 475 hypertensive subjects). Because it was not the primary purpose of this study, we did not investigate it further.
Plasma aldosterone levels are affected by body position. Plasma aldosterone levels were higher in the supine position than in the standing position in normotensive subjects (4.0Ϯ0.2 versus 6.3Ϯ0.4 ng/dL). 25 Reported mean levels of aldosterone were 2.25 ng/dL in men and 2.29 ng/dL in women in the supine position. 28 We measured them in the sitting position. The mean levels of aldosterone were 3.32 ng/dL in men and 3.20 ng/dL in women. There were no subjects with high aldosterone levels. Because the normal range of plasma aldosterone by radioimmunoassay in the sitting position is 3.57 to 24.0 ng/dL in the laboratory, the plasma aldosterone levels measured in the sitting position in the present study were intermediate to those that we would have expected in the standing and supine positions in both sexes, validating the methodology of our aldosterone measurement.
Prospective Study
Our cross-sectional analysis indicated a positive association between plasma aldosterone levels and insulin resistance. However, this association may be an epiphenomenon. Accordingly, we hypothesized that high levels of plasma aldosterone could predict the development of insulin resistance. Our results confirmed the hypothesis in subjects without insulin resistance at baseline. Although a recent prospective study from the Framingham Offspring Study 29 has demonstrated that higher aldosterone levels are associated with the development of metabolic syndrome, they failed to demonstrate the association of aldosterone with the development of insulin resistance. The reason was not clear, but they stated in their limitations that, for the calculation of HOMA-insulin resistance, they used glucose and insulin 4 years before the baseline examination. Another explanation may be the racial difference, including the demographic backgrounds of the subjects, such as the prevalence of obesity; mean BMI in the Framingham Study was Ϸ28 kg/m 2 versus mean BMI in our study, which was Ϸ23 kg/m 2 . Moreover, because the metabolic syndrome includes obesity, hypertension, and abnormal lipid profiles, the development of metabolic syndrome may be because of changes in BP and/or lipid profiles, not directly related to glucose metabolism. In fact, in their study, only changes in systolic BP and HDL cholesterol were significant at follow-up. 29 Thus, we believe that our study is the first one to demonstrate a significant association between plasma levels of aldosterone and development of insulin resistance in a general population. In this study, we not only confirmed our hypothesis but also showed the extent and magnitude of the association; that is, subjects with plasma aldosterone levels Ն4.7 ng/dL were shown to have a 1.7-fold higher risk of developing insulin resistance in 10 years than those with aldosterone levels Ͻ4.7 ng/dL.
Hypokalemia might be one of causes of insulin resistance. 30 However, there was no relationship of baseline plasma potassium level with development of insulin resistance, suggesting no role of hypokalemia for the association between aldosterone and development of insulin resistance.
Renal function is another important determinant of sensitivity to insulin, even at the earliest stage of insufficiency. 31 However, average estimated glomerular filtration rate at the end of follow-up was 60.2Ϯ10.9 mL/min per 1.73 m 2 (range: 32.4 -125.3 mL/min per 1.73 m 2 ). The estimated glomerular filtration rate of subjects who developed insulin resistance versus those who did not was 60.0Ϯ10.5 versus 60.5Ϯ10.9 mL/min per 1.73 m 2 , respectively (Pϭ0.622). Significant differences in the predictive value of baseline aldosterone were found only between the highest and the lowest tertiles of aldosterone. The effect of aldosterone in predicting the development of insulin sensitivity was not dose dependent, suggesting that a cutoff value may exist. Accordingly, we calculated cutoff values by receiver-operating characteristic curves (please see http://hyper.ahajournals.org), and the cutoff value was 4.7 ng/dL. This cutoff value of 4.7 corresponded with the value of the highest tertile value shown in Table 5 . Taken together, these findings indicate that this cutoff value may be relevant when considering the association of aldosterone levels and the development of insulin resistance. Subjects with baseline aldosterone levels Ն4.7 ng/dL were 1.7 times more likely to develop insulin resistance after 10 years compared with subjects with aldosterone levels Ͻ4.7 ng/dL. Our findings may be pertinent in the context of a pathophysiological role of aldosterone in glucose metabolism.
Limitations
The limitations of this study are, first, that we did not measure plasma renin activity at baseline; consequently, we might have enrolled subjects with primary aldosteronism. Second, this study was conducted in Japan, where the incidence of obesity is low compared with whites. Third, Ϸ33% were lost to follow-up because of death or refusal to participate in re-examination. Therefore, we limited our analyses to subjects who completed baseline and follow-up examinations. A final limitation is that we could not clarify the types of antihypertensive drugs used during the 10-year period, because antihypertensive drugs were changed frequently by primary physicians to control BP and for adverse effects. 32 
Perspectives
It was reported in patients with primary aldosteronism 15 that normal sensitivity to insulin was restored by treatment with surgery or aldosterone antagonists. 13, 32 Furthermore, it has been well demonstrated that renin-angiotensin system blockers prevent or retard the development of diabetes mellitus. 2, 33, 34 Thus, it would be interesting to examine whether aldosterone blockers could be useful both for treatment of hypertension and for prevention of insulin resistance or even diabetes mellitus in patients who have hypertension with high plasma aldosterone levels.
Conclusions
In conclusion, the present study demonstrated in a general population that high levels of plasma aldosterone predicted the development of insulin resistance after 10 years in subjects without insulin resistance at baseline. 
